Abstract
Background:
Anti-cyclic citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) are established serological markers in rheumatoid arthritis (RA). However, their specific roles in the development of extra-articular manifestations (EAMs) remain a subject of debate.
Objectives:
This study aimed to quantitatively evaluate ACPA and RF titers and determine their predictive value for specific EAMs, particularly rheumatoid vasculitis (RV) and interstitial lung disease (ILD).
Design:
This research was designed as a retrospective cross-sectional study.
Methods:
We analyzed clinical data from 205 patients with RA, categorized into an RA control group (n = 129) and an RA-EAM group (n = 76). Serum ACPA and RF titers were measured using a second-generation chemiluminescent enzyme immunoassay. To validate the findings, a post hoc power analysis was conducted. Receiver operating characteristic (ROC) curves were generated to determine optimal ACPA cutoff values for predicting RV and ILD.
Results:
Serum ACPA titers, but not RF titers, were significantly elevated in patients with ILD and RV compared with those without EAMs (P < .01). To evaluate the diagnostic utility of serum ACPA titers, ROC curve analysis was performed. Receiver operating characteristic curve analysis showed that ACPA had moderate discriminative ability for identifying RV (AUC = 0.755; 95% CI, 0.61-0.88). The optimal cutoff determined by Youden’s index was 120 U/mL (sensitivity 90.0%, specificity 59.7%). For ILD, the AUC was 0.693 (95% CI, 0.59-0.78), with an optimal cutoff value of 42 U/mL (sensitivity 85.0%, specificity 46.5%). ACPA levels in patients with other EAMs did not differ significantly from controls.
Conclusion:
Our results demonstrated that serum ACPA levels were significantly higher in patients with RA-associated ILD and RV compared with those without systemic involvement. Notably, this association was not observed for RF titers. These findings suggest that high-titer ACPAs may serve as a more specific immunological marker for these severe complications than traditional RF.
Registration:
Not applicable.
Keywords: anti-cyclic citrullinated protein antibody, extra-articular manifestations, interstitial lung disease, rheumatoid arthritis, rheumatoid vasculitis
Introduction
Rheumatoid arthritis (RA) is recognized as a complex autoimmune condition that extends beyond synovial inflammation to involve multiple organ systems through extra-articular manifestations (EAMs). 1 Extra-articular manifestations, including rheumatoid vasculitis (RV) and interstitial lung disease (ILD), represent an important systemic component of RA and are associated with increased morbidity and mortality.1,2
Anti-cyclic citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) are serological hallmarks of RA and have been incorporated into the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA. 3 Both factors are widely measured in clinical practice due to their high specificity for RA. 4 Furthermore, the presence of ACPAs and/or RF is associated with a poor prognosis in RA, 5 with ACPAs being a stronger prognostic indicator of rapid disease progression. 6 Anti-cyclic citrullinated protein antibody–positive patients with RA are more likely to develop erosive disease compared with ACPA-negative patients, as demonstrated via radiography and ultrasonography. 7
Although ACPAs and RF are fundamental to the current classification and prognosis of RA, the relationship between autoantibody levels and the occurrence of EAMs remains controversial. Previous studies have reported conflicting findings regarding the association between seropositivity and systemic complications of RA. For example, Turesson et al 8 demonstrated that both RF and ACPAs are associated with severe extra-articular disease, including RV, suggesting that autoantibody-positive RA represents a more aggressive disease phenotype. In contrast, other studies have reported weaker or inconsistent associations between autoantibody levels and specific manifestations, highlighting the heterogeneity of RA and differences in study design, patient populations, and outcome definitions.9,10 Recent imaging studies have demonstrated that subclinical lung abnormalities are frequently observed in patients with RA, and ILD has been reported in a substantial proportion of cases. 11 In addition, large cohort studies have confirmed that EAMs remain a major clinical challenge in RA, even in the era of advanced therapies. 12
Despite these observations, the extent to which autoantibody levels—particularly high-titer ACPAs—contribute to the development of specific EAMs such as ILD and RV remains unclear. While some studies suggest a strong association between autoantibody positivity and systemic disease manifestations, others have failed to demonstrate a consistent relationship. This inconsistency underscores the need for further investigation, particularly focusing on quantitative autoantibody levels and their relationship with distinct EAM subtypes.
To address this gap, the present study investigates the association between high-titer autoantibodies and the risk of severe EAMs, with a particular focus on RV and ILD.
Methods
Study Design and Ethical Considerations
This research was designed as a retrospective cross-sectional study. The reporting of this study conforms to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. The study protocol received formal approval from the Institutional Review Boards of Zama General Hospital and Showa University Hospital (approval no. #ZA-28). In accordance with the Declaration of Helsinki, informed consent was obtained from all participants via an opt-out mechanism.
Participants and Selection Criteria
We performed a comprehensive review of medical records for patients diagnosed with RA at our institutions between April 2016 and November 2024.
Inclusion criteria. Patients were eligible if they met the 2010 ACR/EULAR classification criteria for RA. 3
Exclusion criteria. Patients with overlapping connective tissue diseases (other than secondary Sjögren syndrome) or those with incomplete clinical data were excluded from the primary analysis.
Group classification. A total of 205 patients were enrolled and categorized into 2 cohorts: (1) the RA control group (n = 129), consisting of patients without any clinical evidence of EAMs, and (2) the RA-EAM group (n = 76), comprising individuals with at least one documented EAM.
Definitions of EAMs
Extra-articular manifestations were defined as the presence of systemic features, including the following:
Rheumatoid vasculitis: Confirmed histologically through skin, muscle, or sural nerve biopsies showing leukocytoclastic vasculitis or fibrinoid necrosis of the vessel wall.
Interstitial lung disease: Identified via high-resolution computed tomography (HRCT) exhibiting reticular patterns, ground-glass opacities, or honeycombing, evaluated independently by 2 expert radiologists.
Other EAMs. Included Sjögren syndrome (according to the revised classification criteria), 13 neuropathy, serositis (pleuritis/pericarditis), epi-scleritis, peripheral neuropathy, and multiple rheumatoid nodules.
Laboratory Measurements
Serum Collection and Laboratory Measurements
For the RA control group, venous blood samples were collected from treatment-naïve patients at their initial clinical presentation, before the initiation of any disease-modifying antirheumatic drugs or corticosteroids. For patients in the EAM subgroups, including those with ILD and RV, serum samples were obtained at the time the EAMs was diagnosed or during its clinically active phase. Thus, the timing of serum sampling differed between the RA control and EAM groups. Disease duration at the time of sampling is presented in Tables 1 and 2. Anti-cyclic citrullinated protein antibody titers were quantified using a second-generation chemiluminescent enzyme immunoassay (Architect anti-CCP; Abbott Japan), with a positivity threshold of >4.5 U/mL.
Table 1.
Characteristics of Patients With RA (With and Without EAMs).
| Group | RA | EAM-RA |
|---|---|---|
| N | 129 | 76 |
| Sex (female), % | 72.7 | 63.6 |
| Age, mean (SD) | 61.4 (14.8) | 65.1 (12.5) |
| Disease duration, mean (SD) | 5.9 (3.8) | 6.9 (5.0) |
| CRP, median (IQR) | 1.0 (0.3-2.1) | 1.9 (0.6-4.0)** |
| RF, median (IQR) | 46.0 (20-132) | 82.5 (21.3-210.0) |
| MMP-3, median (IQR) | 98.0 (66.0-197.5) | 123.5 (63.3-215.5) |
| ACPA, median (IQR) | 65.0 (2.1-213.0) | 133.0 (32.8-355.3)** |
| MTX, % | 73.6 | 57.9 |
| PSL, % | 35.7 | 57.7* |
| Biologics, % | 15.6 | 9.2 |
Abbreviations: ACPA, anti-cyclic citrullinated protein antibody; CRP, C-reactive protein; IQR, interquartile range; MMP-3, matrix metalloproteinase 3; MTX, methotrexate; PSL, prednisolone; RF, rheumatoid factor; SD, standard deviation. Continuous variables were compared using the Mann-Whitney U test, and categorical variables were compared using the Fisher exact test.
P < .05. **P < .01.
Table 2.
Comparison of the RA (Control) Group With the EAM-IP, RV, and EAM-Others Subgroups.
| Group | RA (as control) | EAM-ILD | EAM-others | RV |
|---|---|---|---|---|
| N | 129 | 40 | 26 | 10 |
| Sex (female), % | 72.7 | 62.5 | 53.8 | 40 |
| Age, mean SD | 61.4 (14.8) | 67.4 (13.0)* | 61.4 (12.0) | 70.5 (9.8) |
| Disease duration, mean (SD) | 5.9 (3.8) | 5.4 (2.5) | 6.4 (4.2) | 8.1 (5.1) |
| CRP, median (IQR) | 1.0 (0.3-2.1) | 1.6 (0.5-3.0) | 1.2 (0.6-3.9) | 6.0 (2.8-9.6)*** |
| RF, median (IQR) | 46.0 (20-132) | 87.0 (23.0-252) | 56.0 (15.0-168.0) | 204.5 (31.5-242.0) |
| MMP-3, median (IQR) | 98.0 (66.0-197.5) | 112.0 (58.5-209.0) | 123.0 (62.5-226.0) | 162.5 (88.5-559.8) |
| ACPA, median (IQR) | 65.0 (2.1-213.0) | 180.0 (60.9-644.5)*** | 42.0 (5.0-121.5) | 273.5 (152.3-424.8)* |
| MTX, % | 73.6 | 47.5 | 69.2 | 70 |
| PSL, % | 35.7 | 65*** | 26.9 | 80*** |
| Biologics, % | 15.6 | 7.5 | 11.5 | 10 |
Abbreviations: ACPA, anti-cyclic citrullinated protein antibody; CRP, C-reactive protein; IQR, interquartile range; PSL, prednisolone; RF, rheumatoid factor; SD, standard deviation; MMP-3, matrix metalloproteinase 3; MTX, methotrexate. Continuous variables were compared using the Mann-Whitney U test, and categorical variables were compared using the Fisher exact test.
P < .05. ***P < .001.
RF and Other Markers
Serum RF (cutoff: 15 IU/mL), C-reactive protein (CRP), and matrix metalloproteinase-3 (MMP-3; cutoff: 57 ng/mL), which is a widely used biomarker in Japanese clinical practice for assessing RA disease activity and joint destruction, were measured using latex photometric immunoassays.
Statistical Analysis
Statistical evaluations were conducted using SAS JMP Pro 16.
Comparative analysis. Continuous variables were assessed using the Mann-Whitney U test, whereas categorical data were compared via Fisher exact test.
Diagnostic performance. To evaluate the predictive utility of ACPA for RV and ILD, receiver operating characteristic (ROC) curves were constructed, and the area under the curve (AUC), sensitivity, and specificity were calculated.
Power analysis. A post hoc power analysis was performed using to validate the reliability of the findings despite the subgroup sample sizes.
Significance was set at P < .05.
Results
The characteristics of patients with RA (with and without EAMs) are summarized in Table 1. The RA-EAM group (n = 76) was subdivided into the ILD group (n = 40), RV group (n = 10), and EAM-others group (n = 26), which included patients with Sjögren syndrome (n = 16), pleuritis (n = 2), peripheral neuropathy (n = 2), (epi-)scleritis (n = 3), and multiple rheumatoid nodules (n = 3). Among all 205 patients with RA, the median ACPA titer was 224.5 U/mL (interquartile range [IQR]: 0-3101.0), and 79.5% were ACPA-positive; the median RF titer was 122.0 IU/mL (IQR: 0-796.0), and 80.4% were RF-positive. Significant differences in serum CRP levels (P < .01), ACPA titers (P < .01), and prednisolone (PSL) use (P < .01), but not in RF titers (Table 1), were detected between the RA (n = 129) and RA-EAM (n = 76) groups. There were no significant differences in the use of methotrexate and biologics between these 2 groups. Further statistical analyses compared the RA (control) group with the ILD, RV, and EAM-others subgroups (Table 2). Serum CRP levels were significantly higher in the RV group than in the RA and ILD groups (P < .001). Furthermore, ACPA titers were significantly higher in the ILD (P < .001) and RV (P < .05) groups than in the RA group. In addition, PSL use was significantly more frequent in the RV group than in the RA group (patients without EAMs). On the contrary, there were no significant differences in serum RF or MMP-3 levels among these groups. Furthermore, serum levels of CRP, RF, MMP-3, and ACPA in the EAM-others group did not differ significantly from those in the RA control group. However, the sample sizes for the subgroups within EAM-others were too small (n < 5 each) to allow for a robust statistical comparison. Table 3 indicates ACPA/RF positivity rates and considered more stringent cutoff values. These data demonstrate that ACPA positivity rates are strikingly high in the RV group (100.0% at standard cutoff, 90.0% at ⩾100 U/mL, 70.0% at ⩾200 U/mL) and in the ILD group (92.5%, 67.5%, 47.5%), compared with RA control group (73.6%, 44.2%, 30.2%). Fisher exact test confirmed a statistically significant difference in ACPA positivity (⩾4.5 U/mL) between the ILD group and RA control group (P = .015). Due to the small RV sample with 100% positivity, the Fisher exact test did not reach significance for RV versus RA (P = .12), although the clinical significance of 100% ACPA positivity in the RV group is notable.
Table 3.
Positivity Rates of RF and ACPA Using Standard and High Cutoff Values.
| Group | RF positive (⩾15 IU/mL), % | RF positive (⩾45 IU/mL), % | ACPA positive (⩾4.5 U/mL), % | ACPA positive (⩾100 U/mL), % | ACPA positive (⩾200 U/mL), % |
|---|---|---|---|---|---|
| RV (n = 10) | 100.0 | 70.0 | 100.0 | 90.0 | 70.0 |
| ILD (n = 40) | 90.0 | 65.0 | 92.5 | 67.5 | 47.5 |
| Other EAM (n = 26) | 73.1 | 53.8 | 76.9 | 30.8 | 7.7 |
| RA control group (n = 129) | 78.3 | 55.8 | 73.6 | 44.2 | 30.2 |
Abbreviations: ACPA, anti-cyclic citrullinated peptide antibody; EAM, extra-articular manifestations; ILD, interstitial lung disease; RA, rheumatoid arthritis; RF, rheumatoid factor; RV, rheumatoid vasculitis.
RF and ACPA positivity rates are presented as percentages based on predefined cutoff values.
Comparisons between groups were performed using the Fisher exact test.
Predictive Value of ACPA for RV and ILD
To evaluate the diagnostic utility of serum ACPA titers, ROC curve analysis was performed (Figure 1 and Table 4). Receiver operating characteristic curve analysis showed that ACPA had moderate discriminative ability for identifying RV (AUC = 0.755; 95% CI, 0.61-0.88). The optimal cutoff determined by Youden’s index was 120 U/mL (sensitivity 90.0%, specificity 59.7%). For ILD, the AUC was 0.693 (95% CI, 0.59-0.78), with an optimal cutoff value of 42 U/mL (sensitivity 85.0%, specificity 46.5%).
Figure 1.

Receiver operating characteristic curve analysis of ACPA levels for extra-articular manifestations in rheumatoid arthritis.
(A) ROC curve for predicting rheumatoid vasculitis (RV) from RA controls (AUC = 0.755). (B) ROC curve for predicting interstitial lung disease (ILD) from RA controls (AUC = 0.693).
Table 4.
Receiver Operating Characteristic (ROC) Curve Analysis of ACPA for Predicting Extra-articular Manifestations in RA.
| Group | ILD | RV |
|---|---|---|
| AUC | 0.693 | 0.755 |
| 95% CI | 0.59-0.78 | 0.61-0.88 |
| Cutoff of ACPA, U/mL | ⩾42 | ⩾120 |
| Sensitivity, % | 85.0 | 90.0 |
| Specificity, % | 46.5 | 59.7 |
Abbreviations: ACPA, anti-cyclic citrullinated peptide antibody; AUC, area under the curve; CI, confidence interval; ILD, interstitial lung disease; RA, rheumatoid arthritis; RV, rheumatoid vasculitis.
Receiver operating characteristic curve analysis was performed to evaluate the discriminative ability of ACPA levels for identifying RV and ILD compared with RA controls. The AUC, 95% CI, optimal cutoff values (determined using Youden’s index), sensitivity, and specificity are presented.
Post hoc power analysis of ACPA levels showed adequate power for the comparison between the ILD group and RA controls (power = 0.96), whereas the RV comparison was underpowered due to the small sample size (n = 10, power = 0.297) in Table 5. In contrast, the effect size for RF levels was small to medium (Cohen d = 0.315 [RV], 0.266 [ILD]), resulting in a post hoc power of 0.160 (RV) and 0.312 (ILD). This suggests that the analysis for RF may have been underpowered, with a higher risk of a type II error.
Table 5.
Post Hoc Power Analysis for Comparisons of ACPA Levels Between EAM Subgroups and RA Controls.
| Comparison | n (EAM) | n (RA) | Effect size (Cohen’s d) | Post hoc power (α = .05) |
|---|---|---|---|---|
| ACPA: RV vs RA | 10 | 129 | 0.468 | .297 |
| ACPA: ILD vs RA | 40 | 129 | 0.591 | .960 |
| ACPA: other vs RA | 26 | 129 | 0.165 | .120 |
Abbreviations: ACPA, anti-cyclic citrullinated peptide antibody; EAM, extra-articular manifestations; ILD, interstitial lung disease; RA, rheumatoid arthritis; RV, rheumatoid vasculitis.
Effect sizes were calculated using Cohen d, and statistical power was estimated based on a 2-sided significance level of α = .05.
Discussion
Overview of Findings
In this retrospective analysis, we investigated the clinical correlation between autoantibody titers (ACPA and RF) and the prevalence of EAMs, with a specific focus on RV and ILD. Our results demonstrated that serum ACPA levels were significantly higher in patients with RA-associated ILD and RV compared with those without systemic involvement. Notably, this association was not observed for RF titers. These findings suggest that high-titer ACPAs may serve as a more specific immunological marker for these severe complications than traditional RF.
Association With ILD and RV
An AUC between 0.7 and 0.8 is generally considered to indicate moderate discriminative performance, whereas values between 0.6 and 0.7 suggest limited discrimination. Therefore, the observed AUC of 0.755 for RV indicates that ACPA may have potential clinical utility as a marker for identifying patients at risk of RV, although its diagnostic accuracy remains moderate. In contrast, the AUC of 0.693 for ILD indicates weaker discriminative performance, suggesting that ACPA alone may be insufficient as a predictive biomarker for ILD in RA.
The optimal cutoff values determined by Youden’s index were ACPA ⩾ 42 U/mL for ILD. While some studies found no significant difference in ACPA positivity between EAM and non-EAM groups,9,12 the relatively high sensitivity observed for both outcomes indicates that elevated ACPA levels may be useful for identifying patients at increased risk of extra-articular disease. However, the specificity was moderate, particularly for ILD, suggesting that ACPA should not be used as a standalone diagnostic tool but rather as part of a broader clinical assessment.
Reasons for Inconsistency in Previous Literature
The association between ACPAs/RF and EAMs has remained inconclusive across various studies as discussed above. Several factors may account for these discrepancies:
Genetic and ethnic differences. Variations in HLA-DRB1 alleles among different populations (e.g., Asian vs white) are known to influence ACPA production and EAM susceptibility.14,15
Treatment heterogeneity. The use of methotrexate and biologics can suppress RF levels, whereas ACPA titers remain relatively stable, potentially masking associations in certain cohorts.16,17
Diagnostic criteria. Differences in the sensitivity of imaging (HRCT for ILD) and the requirement for histopathological confirmation of RV can lead to variations in EAM detection rates.
Disease duration and activity. Variations in the timing of serum collection relative to disease onset and active inflammation (as indicated by CRP or DAS28) may further contribute to conflicting results.
Pathophysiological Implications
The biological plausibility of the association between ACPA and EAMs may be explained by several immunopathological mechanisms. Anti-cyclic citrullinated protein antibody recognizes citrullinated proteins generated during inflammatory processes, and these immune complexes can activate complement pathways and promote systemic inflammation in both the joints and the lungs.18,19
The observed association between elevated ACPA levels and ILD is consistent with previous reports, suggesting that the lung may serve as an initial site of citrullination and autoantibody production in RA.10,11,20 Citrullinated proteins and ACPA-producing B cells have been identified in pulmonary tissues, even in individuals without clinically apparent joint disease.21,22 In addition, lung abnormalities detectable by HRCT have been observed in ACPA-positive individuals prior to the onset of arthritis. 23 These findings support the concept that the lung may represent an early site of RA-related autoimmunity. In this context, the elevated ACPA levels observed in patients with RA-associated ILD in the present study may reflect a shared immunological pathway linking systemic autoimmunity and pulmonary inflammation.
In RV, immune complex deposition in small-sized and medium-sized vessels is thought to play a central role in vascular injury. 24 High titers of ACPA may therefore contribute to the formation of circulating immune complexes that enhance vascular inflammation and endothelial damage.25,26 Previous research has identified elevated sCX3CL1 in patients with RV, which correlates with markers of vascular injury like ICAM-1. 27 High-titer ACPAs may orchestrate this aberrant cytokine environment, facilitating endothelial injury through the formation of immune complexes or by inducing pro-inflammatory T-cell responses.
Limitations
The present study has several limitations.
First, due to its retrospective design, standardized disease activity scores (such as DAS28) were not available for all participants at the time of serum sampling. In addition, the retrospective cross-sectional design limits the ability to establish causal relationships between ACPA levels and the development of EAMs. Consequently, we could not fully adjust for the potential confounding effect of overall RA disease activity. In addition, the timing of serum sampling differed between the RA control and EAM groups, which may have introduced heterogeneity related to disease duration, disease activity, and treatment exposure at the time of sampling. Second, serum MMP-3 is a widely used biomarker in Japanese clinical practice for assessing RA disease activity and joint destruction. Although differences of MMP-3 titer between the 3 groups in our results were not significant, the emerging role of MMPs and their tissue inhibitors as biomarkers in connective tissue disease-related ILD was suggested by a recent report by Pulito-Cueto et al. 28 The measurement of additional MMPs may provide further insight and should be explored in future studies. Third, the study was conducted at a single center with a predominantly Japanese patient population, which may limit the generalizability of the findings to other ethnic groups. Finally, the relatively small number of patients with specific EAMs, particularly RV, may have reduced the statistical precision of subgroup analyses.
Conclusion
Despite these limitations, the present study provides additional evidence supporting the association between elevated ACPA levels and systemic manifestations of RA. Our findings suggest that high ACPA titers may reflect a more aggressive immunological phenotype characterized by increased risk of extra-articular disease. Although the discriminative performance observed in this study was moderate, the relatively high sensitivity of the identified ACPA cutoff values suggests that measurement of ACPA levels may contribute to risk stratification in routine clinical practice. Future prospective studies incorporating larger cohorts and longitudinal follow-up will be necessary to determine whether ACPA levels can serve as a predictive biomarker for the development of extra-articular complications in RA.
Footnotes
ORCID iDs: Tsuyoshi Kasama
https://orcid.org/0000-0002-3871-6456
Atsushi Kusaba
https://orcid.org/0009-0006-1455-1788
Takeo Isozaki
https://orcid.org/0000-0002-8621-7643
Nobuyuki Yajima
https://orcid.org/0000-0002-8292-3962
Ethics Approval and Consent to Participate: This study was conducted in accordance with the protocols approved by The Human Subjects Research Committees of Zama General Hospital and Showa University Hospital (approval no. #ZA-28). The research was performed in compliance with the provisions of the Declaration of Helsinki. Informed consent was obtained from all participants through an opt-out procedure approved by the ethics committees.
Author Contributions: All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work. Specific contributions are as follows:
Tsuyoshi Kasama: Conceptualization, investigation, analysis, and writing (original draft and review & editing).
Atsushi Kusaba: Conceptualization, investigation, methodology, analysis, and critical review of the manuscript.
Tomohiko Kanbe, Hiroshi Sunami, Saiji Kondo, and Hiroki Yamashita: Investigation, methodology, and analysis.
Takeo Isozaki and Nobuyuki Yajima: Investigation, methodology, analysis, and critical review of the manuscript.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Data Availability Statement
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.*
References
- 1. Conforti A, Di Cola I, Pavlych V, et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev. 2021;20(2):102735. [DOI] [PubMed] [Google Scholar]
- 2. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25(3):360-366. [DOI] [PubMed] [Google Scholar]
- 3. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588. [DOI] [PubMed] [Google Scholar]
- 4. Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum. 2009;61(11):1472-1483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-977. [DOI] [PubMed] [Google Scholar]
- 6. van Heemst J, van der Woude D, Huizinga TW, Toes RE. HLA and rheumatoid arthritis: how do they connect. Ann Med. 2014;46(5):304-310. [DOI] [PubMed] [Google Scholar]
- 7. Grosse J, Allado E, Roux C, et al. ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography. Rheumatol Int. 2020;40(4):615-624. [DOI] [PubMed] [Google Scholar]
- 8. Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(1):59-64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004;63(12):1587-1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2007;8:37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Salaffi F, Carotti M, Di Carlo M, Tardella M, Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities. Medicine (Baltimore). 2019;98(38):e17088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Bonfiglioli KR, de Medeiros Ribeiro AC, Carnieletto AP, et al. Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multi-centric cohort. Adv Rheumatol. 2023;63(1):34. [DOI] [PubMed] [Google Scholar]
- 13. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-558. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum. 2005;52(12):3813-3818. [DOI] [PubMed] [Google Scholar]
- 15. Furuya T, Hakoda M, Ichikawa N, et al. Differential association of HLA-DRB1 alleles in Japanese patients with early rheumatoid arthritis in relationship to autoantibodies to cyclic citrullinated peptide. Clin Exp Rheumatol. 2007;25(2):219-224. [PubMed] [Google Scholar]
- 16. Alarcón GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum. 1990;33(8):1156-1161. [DOI] [PubMed] [Google Scholar]
- 17. De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):299-302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Bongartz T, Cantaert T, Atkins SR, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2007;46(1):70-75. [DOI] [PubMed] [Google Scholar]
- 19. Perry E, Kelly C, Eggleton P, De Soyza A, Hutchinson D. The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury. Rheumatology (Oxford). 2014;53(11):1940-1950. [DOI] [PubMed] [Google Scholar]
- 20. Aubart F, Crestani B, Nicaise-Roland P, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol. 2011;38(6):979-982. [DOI] [PubMed] [Google Scholar]
- 21. Reynisdottir G, Olsen H, Joshua V, et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis. Ann Rheum Dis. 2016;75(9):1722-1727. [DOI] [PubMed] [Google Scholar]
- 22. Holers VM, Demoruelle MK, Kuhn KA, et al. Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction. Nat Rev Rheumatol. 2018;14(9):542-557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Joshua V, Hensvold AH, Reynisdottir G, et al. Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis. RMD Open. 2020;6(2):e001278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Voskuyl AE, Hazes JM, Zwinderman AH, et al. Diagnostic strategy for the assessment of rheumatoid vasculitis. Ann Rheum Dis. 2003;62(5):407-413. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Breedveld FC, Heurkens AH, Lafeber GJ, van Hinsbergh VW, Cats A. Immune complexes in sera from patients with rheumatoid vasculitis induce polymorphonuclear cell-mediated injury to endothelial cells. Clin Immunol Immunopathol. 1988;48(2):202-213. [DOI] [PubMed] [Google Scholar]
- 26. Turesson C, Englund P, Jacobsson LT, et al. Increased endothelial expression of HLA-DQ and interleukin 1alpha in extra-articular rheumatoid arthritis. Results from immunohistochemical studies of skeletal muscle. Rheumatology (Oxford). 2001;40(12):1346-1354. [DOI] [PubMed] [Google Scholar]
- 27. Matsunawa M, Isozaki T, Odai T, et al. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 2006;54(11):3408-3416. [DOI] [PubMed] [Google Scholar]
- 28. Pulito-Cueto V, Atienza-Mateo B, Batista-Liz JC, et al. Matrix metalloproteinases and their tissue inhibitors as upcoming biomarker signatures of connective tissue diseases-related interstitial lung disease: towards an earlier and accurate diagnosis. Mol Med. 2025;31(1):70-84. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.*
